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Survivin inhibits apoptosis and promotes mitosis. We determined whether nuclear or cytoplasmic localisation of survivin predicts
survival of 48 patients with resected non-small-cell lung cancer (NSCLC). Patients with nuclear staining of survivin had significantly
worse survival (relative risk: 3.9, P¼0.02). Therefore, survivin may be a biomarker for NSCLC.
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Survivin was initially identified as an inhibitor of apoptosis. Its
expression is undetectable in most terminally differentiated
normal tissues, but is at high levels in various malignancies as
well as embryonic and fetal tissues (Salvesen and Duckett, 2002).
Survivin expression is upregulated in all phases of cell cycle, and
the cancer-specific activity of survivin promoter was detected both
in vivo and in vitro (Bao et al, 2002). Deletion of survivin resulted
in a catastrophic defect of microtubule assembly, with absence of
mitotic spindles, disorganised tubulin aggregates and multinuclea-
tion, in the survivin knockout mice (Uren et al, 2000). Colocalisa-
tion of survivin with Aurora-B and the inner centromere protein
(INCENP) suggests that these proteins interact throughout mitosis
and are essential for chromosome condensation and segregation as
well as the completion of cytokinesis (Adams et al, 2001). Several
studies have shown that survivin is a prognostic indicator for poor
survival in several malignancies (Adida et al, 2000; Chakravarti
et al, 2002; Kennedy et al, 2003; Trieb et al, 2003). Survivin protein
level examined by immunostaining was associated with vascular
invasion and poor survival (Ikehara et al, 2002). However, the
predictive value of survivin mRNA examined by RT–PCR is
contradictory between two independent studies (Monzo et al, 1999,
Falleni et al, 2003). Survivin staining was found in both nucleus
and cytoplasm of non-small-cell lung cancer (NSCLC) (Falleni et al,
2003). Nuclear survivin rather than the cytoplasmic staining was
shown to be predictive of poor survival in patients with
oesophageal cancers (Grabowski et al, 2003). Since survivin has
both nuclear and cytoplasmic targets and is involved in regulation
of mitosis and apoptosis, we determined the predictive value of
nuclear vs cytoplasmic staining of survivin among patients with
resected NSCLC.
METHODS
Patients
Archived tissue blocks from 1999 to 2002 were retrieved from the
files of Vanderbilt University and the Nashville Veterans Affairs
Medical Center pathology departments, according to the approved
IRB protocol (010178). For all tissue blocks, the H&E-stained
sections were reviewed by two pathologists who specialise in lung
cancer. Table 1 summarises the clinical and molecular character-
istics of 48 patients with NSCLC. Patients underwent surgical
resection with hilar and mediastinal lymph node sampling. None
of these patients received neoadjuvant chemotherapy or radio-
therapy. Clinical data was obtained from the tumour registry and
hospital charts at the Vanderbilt Medical Center.
Immunohistochemistry
Paraffin-embedded material was available in a set of 48 individual
tumours for evaluation of nuclear and cytoplasmic staining of
survivin. These studies were carried out using a standard avidin–
biotin–peroxidase complex technique, with a mouse monoclonal
antibody against survivin (Santa Cruz Biotech, Santa Cruz,
California, sc-17779). Three separate sections from each case were
examined by the immunohistochemistry method. Staining was
assessed in 5–10 high-powered fields at  400 magnification.
Survivin immunoreactivity was evaluated semiquantitatively based
on the intensity of staining. It was scored as: 1þ (weak); 2þ
(moderate); and 3þ (intense). Cases with no or weak staining
were considered negative, whereas those with moderate to intense
staining were considered as positive. The highest score among the
three tissue sections was entered for statistical analyses.
Statistical analysis
For lifetime data analyses, the possible risk factors, for example,
nuclear survivin, were compared for survival with the Kaplan–
Meier estimates and log-rank tests. The proportional hazards
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ymodel was used for adjusted tests of significance and estimates of
odds ratios. The unadjusted and adjusted 95% confidence intervals
(CI) of survival were calculated and reported for univariate and
multivariate statistical models. All tests of significance were two
sided, and differences were considered statistically significant
when P-value was o0.05. SAS version 8.2 and S-Plus 6 were used
for all analyses.
RESULTS
Cytoplasmic and nuclear staining of survivin in the tissue
samples of NSCLC
We have performed immunohistochemistry analyses on tissue
cores containing NSCLCs from 48 patients who underwent surgical
resections at Vanderbilt University Medical Center from 1999 to
2002. Figure 1 shows a tissue core stained with the sc-17779 mouse
monoclonal antibody. As shown, prominent nuclear staining was
observed. A total of 32 cases (67%) were scored as positive for
nuclear staining, whereas 39 cases (83%) were scored as positive
for cytoplasmic staining. A totl of 19 cases (44%) had positive
staining in both cytoplasm and nucleus.
Nuclear survivin is associated with poor survival in
resected NSCLC
In order to determine whether immunohistochemistry of survivin
staining has any prognostic value, we examined the association
between nuclear or cytoplasmic staining of survivin with overall
survival among the 48 patients with resected NSCLC. No difference
in survival was detected when the data was analysed by patients’
age or sex, tumour histology or grade, or lymph node status.
However, T stage was significantly associated with poor survival as
shown in Table 1. As for survivin staining, nuclear survivin
positivity was significantly associated with poor survival (P¼0.01,
median survival of 248 days, 95% CI: 68–458 days), whereas
cytoplasmic staining of survivin was not, as shown in Figure 2.
This was confirmed by multivariate analyses, which demonstrated
a relative risk of 3.9 in the patients with positive nuclear survivin
(P¼0.02), as shown in Table 2.
DISCUSSION
In this study, we have found that the nuclear presence of survivin
was associated with poor survival in patients with NSCLC. Both
mRNA and protein levels of survivin were shown to predict
unfavourable survival in patients with resected NSCLC (Monzo
et al, 1999; Ikehara et al, 2002). Since survivin has dual function in
apoptosis and mitosis depending upon its cellular localisation, the
predictive value of nuclear vs cytoplasmic staining of survivin has
been investigated in a number of malignancies. When nuclear or
cytoplasmic staining of survivin was scored separately, nuclear
staining was linked with favourable prognosis in gastric cancer
(Okada et al, 2001), breast cancer (Kennedy et al, 2003) and
osteosarcoma (Trieb et al, 2003), whereas cytoplasmic survivin was
not found to be prognostic. In contrast, a recent study in
oesophageal cancers showed that nuclear survivin was associated
with poor survival (Grabowski et al, 2003). Our results in NCSLC
also demonstrated a poor prognostic value of nuclear survivin. The
prognostic difference of nuclear survivin among these studies
appears to be tumoor specific. Relative importance of nuclear
survivin in mitosis may vary among different tumour types and
may predict differently the responses to various cancer type-
specific therapies, which ultimately determine the overall survival
of cancer patients. Nuclear and cytoplasmic pools of survivin have
their distinct roles (Fortugno et al, 2002). It has been shown that
survivin splice variants had different subcellular localisations
(Mahotka et al, 2002). Survivin-delta Ex3 is preferentially localised
in the nucleus, whereas survivin and survivin 2B isoforms are
found in the cytoplasm. However, survivin-2B is nonantiapoptotic.
It is not surprising that the cytoplasmic level is not prognostic
since the IHC staining is unable to discriminate the splicing
variants and represents the combined level of two survivin variants
with opposing effects on apoptosis. The RNA level of survivin 2B
(nonantiapoptotic) detected by RT–PCR was, however, found
decreased in advanced stages of renal (Mahotka et al, 2002) and
gastric cancers (Krieg et al, 2002).
Table 1 Association of clinical variables and survivin staining with overall
survival by the log-rank test
Variable
Number of
patients
Median
survival
(days)
95% CI of
median
survival P-value
Age (years)
o60 22 458 (294, NR) NS
X60 26 NR (133, NR)
Sex
Female 18 NR (452, NR) NS
Male 28 NR (292, NR)
Grade
I 5 NR (NR, NR) NS
II 20 858 (179, NR)
III 14 292 (122, NR)
T-stage
12 5 N R ( N R , N R ) o.0001
2 19 458 (292, NR)
30
4 4 64 (12, 204)
Node stage
0 36 NR (452, NR) NS
1 and 2 12 235 (122, NR)
Nuclear survivin
Neg 40 NR (440, NR) 0.0116
Pos 8 248 (68, 458)
Cytoplasmic survivin
Neg 18 858 (235, NR) NS
Pos 30 469 (292, NR)
NR¼not reached; NS¼not significant.
Figure 1 Cytoplasmic and nuclear staining of NSCLC: one of the tissue
cores containing NSCLC was stained with the mouse monoclonal antibody
against survivin, sc-17779.
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kinase and INCENP, which play essential roles in chromosomal
segregation during the exit of mitosis (Honda et al, 2003).
Knockdown and inhibition of survivin resulted in multinucleated
and polyploid cells, which is a phenotype of mitotic arrest (Uren
et al, 2000). Therefore, strong expression of survivin in the nucleus
may represent increased mitotic events. On the other hand, in the
cytoplasm, survivin inhibits apoptosis by blocking caspase activity.
So far, it has not been demonstrated that the cytoplasmic survivin
alone predicts clinical outcome. This may result from that the
measurement of cytoplasmic survivin includes the combined level
of two functionally opposing variants. Alternatively, other anti-
apoptotic molecules such as bcl-2 proteins may be more important
players in lung cancers. However, a dominant negative mutant of
survivin, T34A, has been shown to be effective in treating
xenografts of breast cancer by freeing up caspase 9 and thus
promoting apoptosis (Wall et al, 2003). This suggests that survivin
remains a viable therapeutic target in certain cancers (Altieri,
2003).
In summary, nuclear presence of survivin may be an important
prognostic marker for patients with resected NSCLC. Larger
population studies are needed to confirm the value of nuclear
staining of survivin as a prognostic marker. Further investigation
should evaluate the strategies of intervening survivin function for
therapeutics in lung cancer.
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Figure 2 Overall survival was significantly worse among NSCLC patients with positive nuclear survivin staining. The Kaplan–Meier survival curve (P¼0.01
by univariate analysis) is shown.
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